Drug Evaluation in Angina Pectoris
Gianluigi Ardissino · Lionel H. Opie · Stefano Savonitto
2012 оны 12-р сар · Developments in Cardiovascular Medicine 158-р ном · Springer Science & Business Media
Электрон ном
262
Хуудас
reportҮнэлгээ болон шүүмжийг баталгаажуулаагүй Нэмэлт мэдээлэл авах
Энэ электрон номын тухай
Although there are many books on angina, few are devoted to the important problem of how to evaluate drug efficacy in angina pectoris. Drug Evaluation in Angina Pectoris has two fundamental aims: the first is to review the methodological aspects of drug evaluation in stable and unstable angina pectoris; the second is to provide a logical and methodological background for future studies aimed at assessing the ability of medical treatment to improve prognosis.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.
Энэ электрон номыг үнэлэх
Санал бодлоо хэлнэ үү.
Унших мэдээлэл
Ухаалаг утас болон таблет
Андройд болон iPad/iPhone-д Google Ном Унших аппыг суулгана уу. Үүнийг таны бүртгэлд автоматаар синк хийх бөгөөд та хүссэн газраасаа онлайн эсвэл офлайнаар унших боломжтой.
Зөөврийн болон ердийн компьютер
Та компьютерийн веб хөтчөөр Google Play-с авсан аудио номыг сонсох боломжтой.
eReaders болон бусад төхөөрөмжүүд
Kobo Цахим ном уншигч гэх мэт e-ink төхөөрөмжүүд дээр уншихын тулд та файлыг татаад төхөөрөмж рүүгээ дамжуулах шаардлагатай болно. Файлуудаа дэмжигддэг Цахим ном уншигч руу шилжүүлэхийн тулд Тусламжийн төвийн дэлгэрэнгүй зааварчилгааг дагана уу.
